Regenxbio RGNX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$90.05M-34.1% | -$67.15M-8.4% | -$61.94M+12.6% | -$70.87M-1,265% | $6.08M+112% | ||
| $3.86M-0.3% | $3.87M-0.4% | $3.89M-0.5% | $3.91M-1.3% | $3.96M-1.7% | ||
| $8.62M+2.9% | $8.38M-6.9% | $9M+4.0% | $8.65M+1.4% | $8.54M-10.5% | ||
| -$18.25M-3,353% | $561K-91.1% | $6.31M+167% | $2.36M+250% | -$1.57M+80.7% | ||
| $349K+119% | -$1.86M— | —— | —— | -$3.65M— | ||
| -$16.73M-37,287% | $45K-98.4% | $2.75M-76.9% | $11.92M+182% | -$14.49M-35.7% | ||
| $900K+161% | $345K-85.6% | $2.39M+316% | -$1.11M-9.4% | -$1.01M-205% | ||
| -$16K-60.0% | -$10K+37.5% | -$16K0.0% | -$16K+99.5% | -$2.96M— | ||
| -$19K+96.5% | -$537K-1,019% | -$48K-118% | -$22K-320% | $10K+101% | ||
| -$700K— | —— | —— | —— | $39.77M+137,238% | ||
| -$384K— | —— | $2.17M— | —— | $2.03M+205% | ||
| $1.31M+121% | -$6.24M-89,100% | -$7K-100% | $3.35M+49.7% | $2.24M+124% | ||
| -$76.19M-45.7% | -$52.29M+6.6% | -$55.96M-13.4% | -$49.34M-247% | $33.63M+206% | ||
| $1.24M+143% | $508K+3.5% | $491K+25.6% | $391K-61.8% | $1.02M-5.1% | ||
| $70.59M— | —— | —— | -$140.44M-414% | $44.74M+11.1% | ||
| $146K+62.2% | $90K— | $0-100% | $78K-48.0% | $150K+295% | ||
| -$13.64M— | —— | —— | $139.23M+2,503% | -$5.79M— | ||
| -$19.24M+21.0% | -$24.34M— | —— | —— | $72.58M+7,884% | ||
| —— | $71.25K0.0% | $71.25K0.0% | $71.25K0.0% | $71.25K+496% | ||
| $879K-28.5% | $1.23M-32.6% | $1.82M+34.4% | $1.36M+26.6% | $1.07M-4.1% | ||
| $349K+119% | -$1.86M— | —— | —— | -$3.65M— | ||
| -$16.73M-37,287% | $45K-98.4% | $2.75M-76.9% | $11.92M+182% | -$14.49M-35.7% | ||
| -$700K— | —— | —— | —— | $39.77M+137,238% | ||
| -$2.53M+16.0% | -$3.01M-146% | -$1.22M+43.8% | -$2.18M+1.9% | -$2.22M-7.6% | ||
| -$1.71M-2.5% | -$1.66M+1.1% | -$1.68M-0.9% | -$1.67M-1.8% | -$1.64M-1.7% | ||
| $1.31M+121% | -$6.24M-89,100% | -$7K-100% | $3.35M+49.7% | $2.24M+124% | ||
| -$384K— | —— | $2.17M— | —— | $2.03M+205% | ||
| $3.75M-26.5% | $5.11M-3.8% | $5.31M+91.7% | $2.77M+1,099% | -$277K-105% | ||
| -$19K+96.5% | -$537K-1,019% | -$48K-118% | -$22K-320% | $10K+101% | ||
| $648K— | —— | $741K— | —— | $307K— | ||
| $13.38M+38.6% | $9.65M+27.1% | $7.59M+44.4% | $5.26M-6.0% | $5.59M-26.5% | ||
| $828K— | —— | $123K— | —— | $510K— | ||
| $553K— | —— | —— | —— | $178K+110% | ||
| $148K— | —— | —— | —— | $143K+158% | ||
| —— | $124.75K0.0% | $124.75K0.0% | $124.75K0.0% | $124.75K-20.5% | ||
| —— | $8.03M0.0% | $8.03M0.0% | $8.03M0.0% | $8.03M+390% | ||
| —— | $71.25K0.0% | $71.25K0.0% | $71.25K0.0% | $71.25K+496% | ||
| -$77.42M-46.6% | -$52.8M+6.5% | -$56.45M-13.5% | -$49.73M-253% | $32.61M+200% | ||
| -$77.42M-46.6% | -$52.8M+6.5% | -$56.45M-13.5% | -$49.73M-253% | $32.61M+200% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Regenxbio generate?
- Regenxbio (RGNX) generated -$233.8M in operating cash flow over the trailing twelve months.
- What is Regenxbio's free cash flow?
- After $2.6M of capital expenditures, Regenxbio's free cash flow was -$236.4M over the trailing twelve months, down 171.9% year over year.
- Where does Regenxbio's cash flow data come from?
- Every line is extracted from Regenxbio's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
